Resistance to cytarabine and anthracycline-based chemotherapy is a major cause of treatment failure in AML.10 More precisely, CD34+CD38− leukemic cell population, enriched in LSCs, are highly resistant to these and other conventional chemotherapies.21 Therefore new therapies are urgently needed for this deadly disease. Here, CD34 is linked to acute myeloid leukemia.